Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized trial of lumicitabine in hospitalized adults with human metapneumovirus infection
jRCT2080223955Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumicitabine in human metapneumovirus infection (HMPV) and acute respiratory illness (ARI) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Antiviral activity outcomes, Clinical outcomes and 2 more.
02
Drugs
lumicitabine
03
Conditions
human metapneumovirus infection (HMPV)acute respiratory illness (ARI)
Beyond the preview
Go deeper on jRCT2080223955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223955.